Latest Recruitment News

Smart Parking Limited reported a robust half-year result for December 2025, nearly doubling revenue to $62.6 million and boosting adjusted EBITDA by 85%, driven by its US acquisition and international growth.

Judo Capital Holdings has delivered a robust 1H26 result, posting a 26% half-on-half profit before tax increase and upgrading its net interest margin guidance for the second half. The bank’s SME lending franchise continues to expand rapidly, supported by strong deposit growth and a solid capital position.

WT Financial Group Limited has reported a robust 16.1% increase in net revenue for the half-year ending December 2025, underpinned by strategic acquisitions and a pioneering joint venture. The company’s proprietary AI technology and industry consolidation efforts position it well for continued expansion.

Clarity Pharmaceuticals’ Cu-64 SAR-bisPSMA diagnostic agent significantly outperformed the current standard Ga-68 PSMA-11 in detecting prostate cancer recurrence, more than doubling lesion and patient detection rates in a pivotal head-to-head trial.

PeopleIN Limited has appointed co-founder Tom Reardon as its new CEO and Managing Director, signaling continuity in leadership as the company reports a robust unaudited EBITDA of $16.1 million.

EROAD Limited’s CEO Mark Heine has announced his resignation effective June 2026, concluding an 11-year tenure marked by significant company growth across multiple regions.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

The Agency Group Australia reports robust Q2 FY26 growth with a 41% jump in Gross Commission Income and expanding national footprint. The company is accelerating its push into East Coast markets while managing supply constraints in Western Australia.

Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.